Source: International Congress 2015 – Cystic fibrosis: assessment and treatment



Rating:

Share or cite this content

Citations should be made in the following way:
Carsten Schwarz (Berlin, Germany), Anja Thronicke, Claudia Brandt, Carsten Schwarz. A new risk factor predicts ABPA in patients with cystic fibrosis. Eur Respir J 2015; 46: Suppl. 59, 1442

Member's Comments

No comment yet.

Related content which might interest you: Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 How useful is the lung ultrasound in cystic fibrosis? Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Clinical value of lung clearance index (LCI) among patients with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Two-compartment model of gas mixing in patients with asthma and cystic fibrosis Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Annual change of LCI among patients with cystic fibrosis Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 National survey of hearing assessment in patients with cystic fibrosis in the UK Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Lung clearance index predicts pulmonary exacerbations in cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Biomarkers of early relapse of pulmonary exacerbation in cystic fibrosis adult patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Lung MRI findings in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Cystic fibrosis and arthritis in children Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Novel protein biomarkers of bronchiectasis in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 The role of CFTR/ENaC genotype in cystic fibrosis-like phenotypes Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 LATE-BREAKING ABSTRACT: A relative plasma Elafin deficiency in children with cystic fibrosis (CF) is associated with pulmonary disease Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Lung clearance index during pulmonary exacerbation in school-age children with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Genetics, pathophysiology and diagnosis of Cystic fibrosis Source: ERS Skills Course 2016 Year: 2016 Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013